ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment

Permanent link
https://hdl.handle.net/10037/25065
DOI
https://doi.org/10.3390/jcm11020347
Thumbnail
View/Open
article.pdf (1.086Mb)
Published version (PDF)
Date
2022-01-11
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Prezioso, Carla; Ciotti, Marco; Brazzini, Gabriele; Piacentini, Francesca; Passerini, Sara; Grimaldi, Alfonso; Landi, Doriana; Nicoletti, Carolina Gabri; Zingaropoli, Maria Antonella; Iannetta, Marco; Altieri, Marta; Conte, Antonella; Limongi, Dolores; Marfia, Girolama Alessandra; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Palamara, Anna Teresa; Moens, Ugo; Pietropaolo, Valeria
Abstract
Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC). The number of MS patients with viruria increased from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35–40%). Viremia first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.
Publisher
MDPI
Citation
Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini, Grimaldi, Landi, Nicoletti, Zingaropoli, Iannetta, Altieri, Conte A, Limongi, Marfia, Ciardi, Mastroianni, Palamara AT, Moens u, Pietropaolo V. Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. Journal of Clinical Medicine. 2022;11(2)
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (medisinsk biologi) [1103]
Copyright 2022 The Author(s)

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)